EMA to bolster support for medicines targeting unmet medical needs

The European Medicines Agency (EMA) has launched, on 7 March, a scheme designed to strengthen support to medicines that target an unmet medical need – EMA Prime.

The scheme focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients with no treatment options. These medicines are considered priority medicines within the European Union.

Present at the launch event, EU Health Commissioner Vytenis Andriukaitis described the scheme as very important for patients and their families:

“The launch of PRIME is a major step forward for patients and their families that have long been hoping for earlier access to safe treatments for their unmet medical needs, such as rare cancers, Alzheimer’s disease and other dementias.”

Find our more here.